MIR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression

Oncology Reports

Volumn 35, Issue 5, 2016, Pages 2859-2865

  Li, Fujun ^a   Gu, Chaohui ^a   Tian, Fengyan ^a   Jia, Zhankui ^a   Meng, Zhenglei ^a   Ding, Yinghui ^a   Yang, Jinjian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

IL 6; Invasion; LNCaP; MIR 218; Proliferation

Indexed keywords

BETA CATENIN; CYCLIN A1; G PROTEIN COUPLED RECEPTOR; GELATINASE B; INTERLEUKIN 6; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 4; MICRORNA; MICRORNA 218; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; WNT PROTEIN; 3' UNTRANSLATED REGION; IL6 PROTEIN, HUMAN; LGR4 PROTEIN, HUMAN; MIRN218 MICRORNA, HUMAN;

ARTICLE; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; 3' UNTRANSLATED REGION; BINDING SITE; CELL MOTION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION; WNT SIGNALING PATHWAY;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; INTERLEUKIN-6; MALE; MICRORNAS; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; WNT SIGNALING PATHWAY;

EID: 84964047315     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4663     Document Type: Article

References (37)

1. J emal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Culig Z: Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol 2: 231-238, 2014.
3. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
4. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer 7: 256-269, 2007.
5. Cheng I, Witte JS, Jacobsen SJ, Haque R, Quinn VP, Quesenberry CP, Caan BJ and Van Den Eeden SK: Prostatitis, sexually transmitted diseases, and prostate cancer: The California Men's Health Study. PLoS One 5: e8736, 2010.
6. Caruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di Bona D, Forte GI, Lio D, Listì F, Scola L, et al: Polymorphisms of pro-inflammatory genes and prostate cancer risk: A pharmacogenomic approach. Cancer Immunol Immunother 58: 1919-1933, 2009.
7. Klein EA and Silverman R: Inflammation, infection, and prostate cancer. Curr Opin Urol 18: 315-319, 2008.
8. H su SY, Liang SG and Hsueh AJ: Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. Mol Endocrinol 12: 1830-1845, 1998.
9. O'Neill PR, Giri L, Karunarathne WK, Patel AK, Venkatesh KV and Gautam N: The structure of dynamic GPCR signaling networks. Wiley Interdiscip Rev Syst Biol Med 6: 115-123, 2014.
10. de Lau W, Barker N, Low TY, Koo BK, Li VS, Teunissen H, Kujala P, Haegebarth A, Peters PJ, van de Wetering M, et al: Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476: 293-297, 2011.
11. Liu J, Wei W, Guo CA, Han N, Pan JF, Fei T and Yan ZQ: Stat3 upregulates leucine-rich repeat-containing G protein-coupled receptor 4 expression in osteosarcoma cells. Biomed Res Int 2013: 310691, 2013.
12. Dorsam RT and Gutkind JS: G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94, 2007.
13. Zhu YB, Xu L, Chen M, Ma HN and Lou F: GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling. Asian Pac J Cancer Prev 14: 4775-4778, 2013.
14. Luo W, Rodriguez M, Valdez JM, Zhu X, Tan K, Li D, Siwko S, Xin L and Liu M: Lgr4 is a key regulator of prostate development and prostate stem cell differentiation. Stem Cells 31: 2492-2505, 2013.
15. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
16. H wang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780, 2006.
17. Stahlhut Espinosa CE and Slack FJ: The role of microRNAs in cancer. Yale J Biol Med 79: 131-140, 2006.
18. Yang L, Li Q, Wang Q, Jiang Z and Zhang L: Silencing of miRNA-218 promotes migration and invasion of breast cancer via Slit2-Robo1 pathway. Biomed Pharmacother 66: 535-540, 2012.
19. Wu DW, Cheng YW, Wang J, Chen CY and Lee H: Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 70: 10392-10401, 2010.
20. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, et al: MIR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6: e1000879, 2010.
21. H e X, Xiao X, Dong L,Wan N, Zhou Z, Deng H and Zhang X: MIR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol 36: 2065-2075, 2015.
22. H an G, Fan M and Zhang X: microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun 456: 804-809, 2015.
23. Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci 105: 802-811, 2014.
24. H obisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H and Culig Z: Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 7: 2941-2948, 2001.
25. Gu CH, Tian FY, Pu JR, Zheng LD, Mei H, Zeng FQ, Yang JJ, Kan QC, Tong QS: Over-expression of testis-specific expressed gene 1 attenuates the proliferation and induces apoptosis of GC-1spg cells. J Huazhong Univ Sci Technolog Med Sci 34: 535-541, 2014.
26. Ben Jemaa A, Sallami S, Ramarli D, Colombatti M and Oueslati R: The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells. Inflammation 36: 643-650, 2013.
27. H obisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr, Klocker H, Bartsch G and Culig Z: Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 191: 239-244, 2000.
28. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
29. Engelhardt PF, Seklehner S, Brustmann H, Lusuardi L and Riedl CR: Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: Association with asymptomatic inflammatory prostatitis NIH category IV. Scand J Urol 49: 120-126, 2015.
30. Nguyen DP, Li J and Tewari AK: Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int 113: 986-992, 2014.
31. Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z and Cavarretta IT: Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol 186: 2107-2114, 2011.
32. Liang F, Yue J, Wang J, Zhang L, Fan R, Zhang H and Zhang Q: GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway. Med Oncol 32: 49, 2015.
33. U esugi A, Kozaki K-i, Tsuruta T, Furuta M, Morita K, Imoto I, Omura K and Inazawa J: The tumor suppressive microRNA MIR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 71: 5765-5778, 2011.
34. Lerner C, Wemmert S and Schick B: Preliminary analysis of different microRNA expression levels in juvenile angiofibromas. Biomed Rep 2: 835-838, 2014.
35. Wegiel B, Bjartell A, Culig Z and Persson JL: Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 122: 1521-1529, 2008.
36. Ahmad A, Sarkar SH, Aboukameel A, Ali S, Biersack B, Seibt S, Li Y, Bao B, Kong D, Banerjee S, et al: Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis 33: 2450-2456, 2012.
37. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI and Gupta S: Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 1424-1432, 2007.